 Tiziana Life Sciences Ltd NASDAQ:TLSA has announced completion of the in-life portion of a 13-week, Good Laboratory Practice GLP foralumab intranasal pre-clinical study in transgenic HuGEMM CD3 mouse models. The clinical-stage biopharmaceutical company said the study showed that intranasal foralumab administered to the transgenic mice at doses up to 50 microgram μg per rodent was clinically well tolerated. 